VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01666444
Recruitment Status : Unknown
Verified July 2016 by VentiRx Pharmaceuticals Inc..
Recruitment status was:  Active, not recruiting
First Posted : August 16, 2012
Last Update Posted : July 22, 2016
Gynecologic Oncology Group
Information provided by (Responsible Party):
VentiRx Pharmaceuticals Inc.

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Unknown
  Estimated Primary Completion Date : October 2016
  Estimated Study Completion Date : October 2016

Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 March 5, 2017
April 14, 2017